natgillin/translations-raw huggingface dataset:
The European Medicines Agency has deferred the obligation to submit the results of studies with doravirine in one or more subsets of the paediatric population in treatment of human immunodeficiency virus-1 (HIV-1) infection, as per Paediatric Investigation Plan (PIP) decision in the granted indication.
Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja doravirina u jednoj ili više podskupina pedijatrijske populacije u liječenju infekcije virusom humane imunodeficijencije 1 (HIV-1), sukladno odluci o Planu istraživanja u pedijatrijskoj populaciji (engl.
Animal studies do not indicate harmful effects of doravirine on fertility at exposure levels higher than the exposure in humans at the recommended clinical dose (see section 5.3).
Ispitivanja na životinjama ne ukazuju na štetne učinke doravirina na plodnost pri razinama izloženosti višima od onih koje se postižu u ljudi kod primjene preporučene kliničke doze (vidjeti dio 5.3).
• The bottle contains a desiccant protecting the tablets from moisture.
• Boca sadrži sredstvo za sušenje koje tablete štiti od vlage.
At baseline, the median age of subjects was 43 years, 16 % were female, and 24 % were non-white.
Na početku ispitivanja medijan dobi ispitanika bio je 43 godine, 16% bile su žene, a 24% ispitanika nisu bili bijelci.
Patients should be informed that fatigue, dizziness, and somnolence have been reported during treatment with doravirine (see section 4.8).
Bolesnike treba obavijestiti o tome da su tijekom liječenja doravirinom prijavljeni umor, omaglica i somnolencija (vidjeti dio 4.8).
Warnings and precautions Talk to your doctor, pharmacist, or nurse before taking Pifeltro.
Upozorenja i mjere opreza Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Pifeltro.
Effects of other medicinal products on doravirine
Učinci drugih lijekova na doravirin
Note: Both doravirine and efavirenz were administered with emtricitabine/tenofovir disoproxil (FTC/TDF).
Napomena: I doravirin i efavirenz primjenjivali su se s emtricitabinom/tenofovirdizoproksilom (FTC/TDF).
White, oval-shaped, tablet of dimensions 19.00 mm x 9.50 mm, debossed with the corporate logo and 700 on one side and plain on the other side.
Bijela, ovalna tableta dimenzija 19,00 mm x 9,50 mm, s utisnutim logotipom proizvođača i oznakom „700“ na jednoj strani i bez oznake na drugoj strani.
No dose adjustment of doravirine is needed in elderly patients (see section 5.2).
Nije potrebno prilagođavati dozu doravirina u starijih bolesnika (vidjeti dio 5.2).
• if you are taking the following medicines: carbamazepine, oxcarbazepine, phenobarbital, phenytoin (medicines for seizures) rifampicin, rifapentine (medicines for tuberculosis) St. John's wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it mitotane (a medicine to treat cancer) enzalutamide (a medicine to treat prostate cancer) lumacaftor (a medicine to treat cystic fibrosis)
• ako uzimate sljedeće lijekove: karbamazepin, okskarbazepin, fenobarbital, fenitoin (lijekovi za napadaje) rifampicin, rifapentin (lijekovi za tuberkulozu) gospinu travu (Hypericum perforatum, biljni lijek koji se koristi za liječenje depresije i tjeskobe) ili lijekove koji je sadrže mitotan (lijek za liječenje raka) enzalutamid (lijek za liječenje raka prostate) lumakaftor (lijek za liječenje cistične fibroze)
Do not take Pifeltro:
Nemojte uzimati Pifeltro
DOR/3TC/TDF Once Daily ISG
DOR/3TC/TDF doziranje jedanput na dan ISG
Use with CYP3A inducers
Primjena s induktorima CYP3A
• inflammation of the skin due to allergy, redness on the cheeks, nose, chin or forehead, bumps or pimples on the face
• upala kože zbog alergije, crvenilo obraza, nosa, brade ili čela, kvržice ili prištići na licu
What Pifeltro contains
Što Pifeltro sadrži
If you are not sure, talk to your doctor, pharmacist, or nurse before taking Pifeltro.
Ako niste sigurni, razgovarajte s liječnikom, ljekarnikom ili medicinskom sestrom prije nego uzmete Pifeltro.
Pifeltro must be used in combination with other medicines for HIV.
Pifeltro se mora primjenjivati u kombinaciji s drugim lijekovima za liječenje HIV infekcije.
Treatment emergent doravirine resistance associated substitutions may confer cross resistance to efavirenz, rilpivirine, nevirapine, and etravirine.
Supstitucije povezane s rezistencijom na doravirin koje se javljaju tijekom liječenja mogu dovesti do križne rezistencije na efavirenz, rilpivirin, nevirapin i etravirin.
2031 BN Haarlem The Netherlands
2031 BN Haarlem NIZOZEMSKA
• trouble concentrating, memory problems, tingling of hands and feet, stiff muscles, poor quality sleep
• poteškoće s koncentracijom, poteškoće s pamćenjem, trnci u šakama i stopalima, ukočenost mišića, loša kvaliteta sna
Effects on Medicinal Product Levels Geometric Mean Ratio (90 % CI)*
Učinci na geometrijsku srednju vrijednost omjera koncentracija lijeka (90% CI)*
Table 3: Resistance development up to week 96 in protocol defined virologic failure population + early discontinuation population
Tablica 3. Razvoj rezistencije do 96. tjedna u populaciji s izostankom virološkog odgovora definiranog planom ispitivanja i populaciji koja se prijevremeno povukla iz ispitivanja
Co-administration of doravirine and medicinal products that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine.
Istodobna primjena doravirina i lijekova koji su inhibitori CYP3A može povisiti koncentracije doravirina u plazmi.
Effects of doravirine on other medicinal products
Učinci doravirina na druge lijekove
HIV Antiviral Agents Fusion and Entry Inhibitors enfuvirtide
Antivirotici za liječenje HIV infekcije Inhibitori fuzije i ulaska u stanicu enfuvirtid
Excipient with known effect Each film-coated tablet contains 222 mg lactose (as monohydrate).
Jedna filmom obložena tableta sadrži 222 mg laktoze (u obliku hidrata).
DOR + 2 NRTIs
DOR + 2 NRTI-ja
Each film-coated tablet contains 100 mg of doravirine.
Jedna filmom obložena tableta sadrži 100 mg doravirina.
Laboratory strains of HIV-1 harbouring the common NNRTI-associated mutations K103N, Y181C, or K103N/Y181C substitutions in RT exhibit less than a 3-fold decrease in susceptibility to doravirine compared to wild-type virus when evaluated in the presence of 100 % normal human serum.
Laboratorijski sojevi HIV-1 koji nose uobičajene mutacije povezane s rezistencijom na NNRTI-je K103N, Y181C ili supstitucije K103N/Y181C u reverznoj transkriptazi pokazuju manje nego trostruko smanjenje osjetljivosti na doravirin u odnosu na virus divljeg tipa kada su se ispitivali u prisutnosti 100%-tnog normalnog humanog seruma.
Doravirine has been evaluated in a limited number of patients with NNRTI resistance (K103N n=7, G190A n=1); all patients were suppressed to < 40 copies/mL at week 48.
Doravirin se ocjenjivao kod ograničenog broja bolesnika s rezistencijom na NNRTI-je (K103N n=7, G190A n=1); svim je bolesnicima razina HIV-1 RNK u 48. tjednu bila suprimirana na < 40 kopija/ml.
Therefore caution should be used when co-administering doravirine with medicinal products that are sensitive CYP3A substrates that also have a narrow therapeutic window (e.g., tacrolimus and sirolimus).
Stoga je potreban oprez kada se doravirin primjenjuje istodobno s lijekovima koji su CYP3A osjetljivi supstrati i koji uz to imaju i usku terapijsku širinu (npr. takrolimus i sirolimus).
In a pooled analysis combining data from two treatment-naïve trials (P007 and DRIVE-AHEAD), a lower proportion of subjects who discontinued due to an adverse event by week 48 was seen for the combined doravirine (100 mg) treatment groups (2.8 %) compared with the combined EFV treatment group (6.1 %) (treatment difference -3.4 %, p-value 0.012).
U analizi objedinjenih podataka iz dvaju ispitivanja provedenih u bolesnika koji prethodno nisu bili liječeni (P007 i DRIVE-AHEAD), zabilježen je manji udio ispitanika koji su prekinuli liječenje zbog razvoja nuspojave do 48. tjedna u objedinjenim skupinama liječenima doravirinom (100 mg) (2,8%) u usporedbi s objedinjenim skupinama liječenima EFV-om (6,1%) (razlika između liječenja: -3,4%; p-vrijednost: 0,012).
Although a limited number of subjects aged 65 years and over has been included (n=36), no clinically relevant differences in the pharmacokinetics of doravirine have been identified in subjects at least 65 years of age compared to subjects less than 65 years of age in a Phase 1 trial or in a population pharmacokinetic analysis.
Iako je u ispitivanje faze 1 i populacijsku farmakokinetičku analizu bio uključen ograničen broj ispitanika u dobi od 65 ili više godina (n=36), nisu utvrđene klinički značajne razlike u farmakokinetici doravirina u ispitanika u dobi od najmanje 65 godina u usporedbi s onima mlađima od 65 godina.
How Pifeltro works
Kako Pifeltro djeluje
3, 84 % were male, 27 % were non-white, 4 % had hepatitis B and/or C virus co-infection, 10 % had a history of AIDS, 20 % had HIV-1 RNA greater than 100,000 copies per mL, 13 % received ABC/3TC and 87 % received FTC/TDF; these characteristics were similar between treatment groups.
84% bili su muškarci, 27% ispitanika nije bilo bijele rase, 4% istodobno je imalo infekciju virusom hepatitisa B i/ili C, 10% imalo je AIDS u anamnezi, 20% imalo je razinu HIV-1 RNK višu od 100 000 kopija/ml, 13% ih je primalo ABC/3TC, a 87% FTC/TDF; te su značajke bile slične u obje liječene skupine.
Antiviral activity in combination with other HIV antiviral medicinal products The antiviral activity of doravirine was not antagonistic when combined with the NNRTIs delavirdine, efavirenz, etravirine, nevirapine, or rilpivirine; the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, or zidovudine; the PIs darunavir or indinavir; the fusion inhibitor enfuvirtide; the CCR5 co-receptor antagonist maraviroc; or the integrase strand transfer inhibitor raltegravir.
Antivirusna aktivnost kod primjene u kombinaciji s drugim antiviroticima za liječenje HIV infekcije Antivirusna aktivnost doravirina nije bila antagonistička kada se kombinirao s NNRTI-jima delavirdinom, efavirenzom, etravirinom, nevirapinom ili rilpivirinom; NRTI-jima abakavirom, didanozinom, emtricitabinom, lamivudinom, stavudinom, tenofovirdizoproksilom ili zidovudinom; inhibitorima proteaze darunavirom ili indinavirom; inhibitorom fuzije enfuvirtidom; antagonistom koreceptora CCR5 maravirokom; ili inhibitorom prijenosa lanca integrazom raltegravirom.
*NRTIs in DOR arm: FTC/TDF (333) or ABC/3TC (50); NRTIs in DRV+r arm: FTC/TDF (335) or ABC/3TC (48) **Subjects received FTC/TDF
*NRTI-ji u skupini koja je primala doravirin (DOR): FTC/TDF (333) ili ABC/3TC (50); NRTI-ji u skupini koja je primala darunavir pojačan ritonavirom (DRV+r): FTC/TDF (335) ili ABC/3TC (48) **Ispitanici su primali FTC/TDF
P007 was a Phase 2b trial in antiretroviral treatment-naïve HIV-1 infected adult subjects (n = 340).
P007 bilo je ispitivanje faze 2b provedeno u odraslih ispitanika s HIV-1 infekcijom koji prethodno nisu bili liječeni antiretroviroticima (n=340).
Mutagenesis Doravirine was not genotoxic in a battery of in vitro or in vivo assays.
Doravirin nije bio genotoksičan u nizu testova in vitro ili in vivo.
Consistent results were seen for the comparison at study Week 24 in each treatment group.
Rezultati liječenja prikazani su u Tablici 6. Prilikom usporedbe u 24. tjednu ispitivanja, primijećeni su dosljedni rezultati u obje liječene skupine.
In a study comparing 8 subjects with severe renal impairment to 8 subjects without renal impairment, the single dose exposure of doravirine was 31 % higher in subjects with severe renal impairment.
U ispitivanju u kojem se 8 ispitanika s teškim oštećenjem funkcije bubrega uspoređivalo s 8 ispitanika bez oštećenja funkcije bubrega izloženost doravirinu nakon primjene jedne doze bila je 31% veća u ispitanika s teškim oštećenjem funkcije bubrega.
Store in the original bottle and keep the bottle tightly closed in order to protect from moisture.
Čuvati u originalnoj boci, a bocu držati čvrsto zatvorenom radi zaštite od vlage.
Exclusionary NNRTI substitutions were those listed above (DRIVE-FORWARD and DRIVE-AHEAD), with the exception of substitutions RT K103N, G190A and Y181C (accepted in DRIVE-SHIFT).
Isključujuće supstitucije povezane s rezistencijom na NNRTI-je bile su one navedene gore (DRIVE-FORWARD i DRIVE-AHEAD), uz izuzetak supstitucija u reverznoj transkriptazi K103N, G190A i Y181C (prihvaćene u ispitivanju DRIVE-SHIFT).
Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccant.
Jedno pakiranje sadrži bocu od polietilena visoke gustoće (HDPE) zatvorenu polipropilenskim zatvaračem sigurnim za djecu koja sadrži silika-gel kao sredstvo za sušenje.
The administration of a single doravirine tablet with a high-fat meal to healthy subjects resulted in a 16 % and 36 % increase in doravirine AUC and C24, respectively, while Cmax was not significantly affected.
Utjecaj hrane na apsorpciju nakon peroralne primjene Primjena jedne tablete doravirina uz obrok s visokim udjelom masnoća u zdravih ispitanika povisila je AUC i C24 doravirina za 16% odnosno 36%, dok na Cmax nije značajno utjecala.
Pregnancy There are no or limited amount of data from the use of doravirine in pregnant women.
Nema podataka ili su podaci o primjeni doravirina u trudnica ograničeni.
DRV + r + NRTIs*
DRV + r + NRTI-ji*
No clinically relevant pharmacokinetic differences have been identified between men and women for doravirine.
Spol Nisu utvrđene klinički značajne razlike u farmakokinetici doravirina između muškaraca i žena.
Pifeltro contains the active substance doravirine - a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Pifeltro sadrži djelatnu tvar doravirin - nenukleozidni inhibitor reverzne transkriptaze (engl. non-nucleoside reverse transcriptase inhibitor, NNRTI).
Subjects must have been virologically suppressed (HIV-1 RNA < 40 copies/mL) on their baseline regimen for at least 6 months prior to trial entry, with no history of virologic failure, and a documented absence of RT substitutions conferring resistance to doravirine, lamivudine and tenofovir (see section Resistance).
Virološka supresija (HIV-1 RNK < 40 kopija/ml) morala je biti postignuta početnim režimom u ispitanika tijekom najmanje 6 mjeseci prije ulaska u ispitivanje, pri čemu u anamnezi nije zabilježen izostanak virološkog odgovora, uz dokumentiranu odsutnost supstitucija u reverznoj transkriptazi koje donose rezistenciju na doravirin, lamivudin ili tenofovir (vidjeti dio Rezistencija).
Expected:  doravirine sofosbuvir
Očekivano: ↔ doravirin sofosbuvir
What Pifeltro is
Što je Pifeltro
If your doctor decides you should take these medicines with Pifeltro, one tablet of doravirine should be taken twice daily (approximately 12 hours apart).
Ako Vaš liječnik odluči da trebate uzimati te lijekove zajedno s lijekom Pifeltro, morat ćete uzimati jednu tabletu doravirina dvaput na dan (u razmaku od približno 12 sati).
Subsequently F227(L/C/V) or L234I emerged in addition to V106 substitution (double mutants yielding a fold change of > 100).
Nakon toga se uz supstituciju V106 javila i mutacija F227(L/C/V) ili L234I (dvostruke mutacije koje su dovele do promjene > 100 puta u odnosu na početnu vrijednost).
If a patient misses a dose by more than 12 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time.
Ako je od propuštene doze prošlo više od 12 sati, bolesnik ne smije uzeti propuštenu dozu, nego treba uzeti sljedeću predviđenu dozu prema uobičajenom rasporedu.
If you forget to take Pifeltro
Ako prestanete uzimati Pifeltro
No dose adjustment of doravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
Nije potrebno prilagođavati dozu doravirina u bolesnika s blagim (Child-Pugh stadij A) ili umjerenim (Child-Pugh stadij B) oštećenjem funkcije jetre.
In the DRIVE-SHIFT clinical trial, no subjects developed genotypic or phenotypic resistance to DOR, 3TC, or TDF during the initial 48 weeks (immediate switch, N=447) or 24 weeks (delayed switch, N=209) of treatment with DOR/3TC/TDF.
U kliničkom ispitivanju DRIVE-SHIFT, nijedan ispitanik nije razvio genotipsku ili fenotipsku rezistenciju na DOR, 3TC ili TDF uz liječenje DOR/3TC/TDF tijekom početnih 48 tjedana (prelazak bez odgode, N=447) ili tijekom 24 tjedna (odgođeni prelazak, N=209).
At baseline, the median age of subjects was 31 years (range 18-70 years), 85 % were male, 52 % were non-white, 3% had hepatitis B or C co-infection, 14 % had a history of AIDS, 21 % had HIV-1 RNA > 100,000 copies per mL, and 12 % had CD4
Medijan dobi ispitanika na početku ispitivanja iznosio je 31 godinu (raspon: 18 - 70 godina), 85% bili su muškarci, 52% ispitanika nije bilo bijele rase, 3% istodobno je imalo infekciju virusom hepatitisa B ili C, 14% imalo je AIDS u anamnezi, 21% imalo je razinu HIV-1 RNK višu od 100 000 kopija/ml, a 12% ih je imalo broj CD4
In DRIVE-FORWARD, 766 subjects were randomised and received at least 1 dose of either doravirine 100 mg or darunavir + ritonavir 800+100 mg once daily, each in combination with emtricitabine/tenofovir disoproxil (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator.
U ispitivanju DRIVE-FORWARD randomizirano je 766 ispitanika, koji su primili najmanje 1 dozu doravirina od 100 mg ili darunavira + ritonavira od 800 + 100 mg jedanput na dan, svaki u kombinaciji s emtricitabinom/tenofovirdizoproksilom (FTC/TDF) ili abakavirom/lamivudinom (ABC/3TC), prema izboru ispitivača.
Package leaflet: Information for the user Pifeltro 100 mg film-coated tablets doravirine
Uputa o lijeku: Informacije za korisnika Pifeltro 100 mg filmom obložene tablete doravirin
Rare blood creatine phosphokinase increased insomnia includes: insomnia, initial insomnia and sleep disorder depression includes: depression, depressed mood, major depression, and persistent depressive disorder anxiety includes: anxiety and generalised anxiety disorder abdominal pain includes: abdominal pain, and abdominal pain upper abdominal discomfort includes: abdominal discomfort, and epigastric discomfort faeces soft includes: faeces soft and abnormal faeces gastrointestinal motility disorder includes: gastrointestinal motility disorder, and frequent bowel movements rash includes: rash, rash macular, rash erythematous, rash generalised, rash maculo-papular, rash papular, and urticarial alanine aminotransferase increased includes: alanine aminotransferase increased and hepatocellular injury
Pretrage često povišene vrijednosti alanin aminotransferaze manje često povišene vrijednosti lipaze, povišene vrijednosti aspartat aminotransferaze, povišene vrijednosti amilaze, snižene vrijednosti hemoglobina rijetko povišene vrijednosti kreatin fosfokinaze u krvi nesanica uključuje: nesanicu, početnu nesanicu i poremećaj spavanja depresija uključuje: depresiju, depresivno raspoloženje, veliki depresivni poremećaj i perzistirajući depresivni poremećaj anksioznost uključuje: anksioznost i generalizirani anksiozni poremećaj bol u abdomenu uključuje: bol u abdomenu i bol u gornjem dijelu abdomena nelagoda u abdomenu uključuje: nelagodu u abdomenu i nelagodu u epigastriju mekana stolica uključuje: mekanu stolicu te abnormalnu stolicu poremećaj gastrointestinalnog motiliteta uključuje: poremećaj gastrointestinalnog motiliteta i učestala pražnjenja crijeva osip uključuje: osip, makularni osip, eritemski osip, generalizirani osip, makulopapularni osip, papularni osip i urtikariju povišene vrijednosti alanin aminotransferaze uključuju: povišene vrijednosti alanin aminotransferaze i hepatocelularnu ozljedu
If the patient misses a dose of Pifeltro within 12 hours of the time it is usually taken, the patient should take as soon as possible and resume the normal dosing schedule.
Ako je bolesnik propustio uzeti dozu lijeka Pifeltro, a od propuštene doze je prošlo manje od 12 sati, treba je uzeti što je prije moguće i zatim nastaviti s primjenom prema uobičajenom rasporedu.
Expected:  doravirine glecaprevir, pibrentasvir
Očekivano: ↔ doravirin glekaprevir, pibrentasvir
Baseline Regimen = ritonavir or cobicistat-boosted PI (specifically atazanavir, darunavir, or lopinavir), or cobicistat-boosted elvitegravir, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each administered with two NRTIs.
Početni režim = inhibitor proteaze pojačan ritonavirom ili kobicistatom (posebno atazanavir, darunavir ili lopinavir), ili elvitegravir pojačan kobicistatom, ili NNRTI (posebno efavirenz, nevirapin ili rilpivirin), svaki primijenjen s dva NRTI-ja.
+ T'.
+T stanice“.
Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class (see sections 4.4 and 5.1).
Pifeltro je u kombinaciji s drugim antiretrovirusnim lijekovima indiciran za liječenje odraslih osoba s infekcijom virusom humane imunodeficijencije tipa 1 (HIV-1) bez prethodnih ili trenutačnih dokaza rezistencije na lijekove iz skupine nenukleozidnih inhibitora reverzne transkriptaze (engl. non-nucleoside reverse transcriptase inhibitors, NNRTI) (vidjeti dijelove 4.4 i 5.1).
If co-administration cannot be avoided, one tablet of doravirine should be taken twice daily (approximately 12 hours apart).
Ako se istodobna primjena ne može izbjeći, treba uzimati jednu tabletu doravirina dvaput na dan (u razmaku od približno 12 sati).
Therefore, caution is advised when doravirine is administered to patients with severe hepatic impairment (see section 5.2).
Stoga se preporučuje oprez kada se doravirin primjenjuje u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 5.2).
30 months After first opening of the bottle use within 35 days.
Primijeniti unutar 35 dana nakon prvog otvaranja boce.
In both parts of the trial, doravirine and EFV were administered as blinded-therapy and FTC/TDF was administered open-label.
U oba su se dijela ispitivanja doravirin i EFV primjenjivali kao slijepa terapija, dok se kombinacija FTC/TDF primjenjivala otvoreno.
If co-administration with other moderate CYP3A inducers (e.g., dabrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl) cannot be avoided, one 100 mg tablet of Pifeltro should be taken twice daily (approximately 12 hours apart).
Ako se istodobna primjena s drugim umjerenim induktorima CYP3A (npr., dabrafenib, lesinurad, bosentan, tioridazin, nafcilin, modafinil, etiltelotristat) ne može izbjeći, potrebno je uzimati jednu tabletu lijeka Pifeltro od 100 mg dvaput na dan (u razmaku od približno 12 sati).
What Pifeltro looks like and contents of the pack Pifeltro is available as a white, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 700 on one side and plain on the other side.
Pifeltro je bijela, ovalna, filmom obložena tableta s utisnutim logotipom proizvođača i oznakom „700“ na jednoj strani i bez oznake na drugoj strani.
Do not take Pifeltro if the above applies to you.
Pifeltro ako se nešto od navedenog odnosi na Vas.
Clinical isolates containing the Y188L substitution or V106 substitutions in combination with A98G, H221Y, P225H, F227C or Y318F showed a greater than 100-fold reduced susceptibility to doravirine.
Klinički izolati koji su sadržavali supstituciju Y188L ili supstitucije V106 u kombinaciji s mutacijama A98G, H221Y, P225H, F227C ili Y318F pokazivali su više od 100 puta smanjenu osjetljivost na doravirin.
The Phase 3 studies, DRIVE-FORWARD and DRIVE-AHEAD, included previously untreated patients (n = 747) where the following NNRTI substitutions were part of exclusion criteria: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.
U ispitivanjima faze 3, DRIVE-FORWARD i DRIVE-AHEAD, sudjelovali su prethodno neliječeni bolesnici (n=747), a sljedeće supstitucije povezane s rezistencijom na NNRTI-je bile su dio isključnih kriterija: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C,Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.